Description

Aranesp (darbepoetin alpha) solution for injections 100 mcg/ml. syringe 0.3 ml. №1

Ingredients

Active ingredient: Darbepoetin alpha
Other ingredients: Sodium phosphate monobasic monohydrate, sodium phosphate dibasic anhydrous, polysorbate 80, and water for injection.

Dosage

The recommended dosage: The dosage of Aranesp depends on the patient’s condition and response to treatment. It is usually administered as a subcutaneous injection once weekly or once every 2 weeks. The dosage may vary from patient to patient, so follow your healthcare provider’s instructions carefully.

Indications

Aranesp is indicated for:
– Treatment of anemia in patients with chronic kidney disease
– Reduction of transfusion requirements in patients undergoing elective surgery

Contraindications

Do not use Aranesp if:
– You have uncontrolled hypertension
– You have pure red cell aplasia that begins after treatment with Aranesp or other erythropoietin protein drugs

Directions

– Aranesp is for subcutaneous injection only.
– Do not shake the syringe.
– Follow proper injection techniques as instructed by your healthcare provider.

Scientific Evidence

Pharmacological Effects: Aranesp works by stimulating the bone marrow to produce more red blood cells, thus increasing the oxygen-carrying capacity of the blood. This can help improve symptoms of anemia and reduce the need for blood transfusions in certain patients.

Clinical Trials: Clinical studies have shown that Aranesp is effective in treating anemia associated with chronic kidney disease and in reducing transfusion requirements in patients undergoing surgery. For example, a study published in the New England Journal of Medicine demonstrated that darbepoetin alpha effectively increased hemoglobin levels in patients with chronic kidney disease.

Overall, Aranesp has been shown to be a safe and effective treatment option for managing anemia in various clinical settings.

Additional Information

– Store Aranesp in the refrigerator at 2°C to 8°C. Do not freeze.
– Keep the medication out of reach of children.
– Check the product for particles or discoloration before use.

In conclusion, Aranesp (darbepoetin alpha) is a valuable medication for managing anemia in patients with chronic kidney disease and reducing transfusion requirements in surgical patients. Its pharmacological effects on red blood cell production have been well-documented in clinical trials, making it a trusted option for healthcare providers. Always follow your healthcare provider’s instructions for the correct dosage and administration of Aranesp.